多重耐药鲍曼不动杆菌治疗药物研究进展

Research progress of medication treatment of multidrug-resistant acinetobacter baumannii

由于临床上鲍曼不动杆菌的治疗药物选择局限性,同时该菌不断产生新的耐药机制,导致多重耐药鲍曼不动杆菌感染有较高的发病率和死亡率。因此,本文旨对目前多重耐药鲍曼不动杆菌可选用的治疗药物及该治疗领域的最新进展加以综述。

Owing to the selection limition in drugs to control Acinetobacter Baumannii infections in clinic,and its increasing new antimicrobial resistance mechanisms,the morbidity and mortality of Multidrug-resistant Acinetobacter Baumannii（ MDRAB） has raising.This paper aimes to report all available therapeutic options against the MDRAB isolates and present all of the latest developments in the field.